Format

Send to

Choose Destination
J Vasc Surg. 2016 Jun;63(6):1476-82. doi: 10.1016/j.jvs.2015.12.027. Epub 2016 Feb 27.

International experience with endovascular therapy of the ascending aorta with a dedicated endograft.

Author information

1
German Aortic Center, University Heart Center, Hamburg, Germany. Electronic address: n.tsilimparis@uke.de.
2
German Aortic Center, University Heart Center, Hamburg, Germany.
3
Department of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
4
Department of Vascular Surgery, Heart Center, University of Lille, Lille, France.
5
Department of Cardiothoracic Surgery, University of Aarhus, Aarhus, Denmark.
6
Cook Medical, Bloomington, Ind.

Abstract

OBJECTIVE:

The objective of this study was to evaluate the safety and feasibility of a novel stent graft specifically designed for treatment of the ascending aorta.

METHODS:

This was a multicenter, retrospective analysis of all consecutive patients treated with the dedicated Zenith Ascend TAA Endovascular Graft (William Cook Europe, Bjaeverskov, Denmark) for pathologic processes requiring stent grafting of the ascending aorta. The graft is short (6.5 cm), with a delivery system designed for transfemoral placement in the ascending aorta.

RESULTS:

In 10 patients (five men; age, 67 years; range, 26-90 years), the Zenith Ascend graft was implanted for the following indications: dissection (n = 5) and aneurysm (n = 4) of the ascending aorta and fixation of an intraprocedural dislocated aortic valve (n = 1). All patients were judged to be at high risk for open surgery (nine patients were classified as American Society of Anesthesiologists class 3 or class 4). A transfemoral approach was selected in eight cases and a transapical approach in two. All endografts were successfully deployed without intraoperative adverse events at the targeted landing zone. Clinical success in coverage of the lesions was achieved in all cases with the exception of an attempted treatment of an intraprocedural aortic valve implantation dissection that resulted in early mortality. The 30-day survival was 90%. Early neurologic events included one patient with stroke and paraplegia and one patient with a transient ischemic attack. One patient underwent early evacuation of a hemopericardium. There were two late reinterventions for persisting endoleaks. At a mean follow-up of 10 months (range, 1-36 months), three late deaths occurred, with one treatment related, as a result of graft infection.

CONCLUSIONS:

Despite the fact that in this first published series the graft was frequently used as a "rescue tool" outside its intended indication, treatment with the Zenith Ascend graft in this early experience appears to be safe and feasible for repair of ascending aorta pathologic processes in high-risk patients unsuitable for open repair.

PMID:
26926935
DOI:
10.1016/j.jvs.2015.12.027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center